格隆汇12月9日丨健康之路(02587.HK)公告，12月9日耗资94.7万港元回购20万股，回购价格每股4.72- 4.75港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 健康之路股份有限公司 呈交日期： 2025年12月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02587 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存 ...

此外，董事会认为，本公司拥有充足的财务资源，可实施建议购回，且将不会损害其财务状况。建议购 回将不会以导致股份的公众持股量低于上市规则规定的最低百分比的方式进行，亦不会导致本公司股东 根据公司收购及合并守则作出强制性全面要约的责任。 本文源自：智通财经网 智通财经获悉，健康之路(02587)午前涨超3%，截至发稿，涨2.67%，报4.99港元，成交额4653.23万港 元。 消息面上，12月8日，健康之路发布公告，根据现行市况，本公司拟于未来五个月内行使购回授权，于 公开市场上购回本公司已发行股份，总代价不超过1亿港元(建议购回)。董事会认为，建议购回反映本 公司对其业务前景的信心，并将提升股东价值。建议购回将仅在董事会认为合适且符合本公司及其股东 的整体利益时方会进行。 ...

本文源自：财华网 建议购回将完全由公司內部资源提供资金。全球发售股份所得款项净额将不会用于建议购回。 【财华社讯】健康之路(02587.HK)公布，根据现行市况，公司拟于未来五个月內行使购回授权，于公开 市场上购回公司已发行股份，总代价不超过1亿港元。根据购回授权，购回最多87,770,480股公司股份， 相当于于股东周年大会日期已发行股份总数的10%。所购回的任何股份将作为库存股份持有，公司可根 据市场情况及集团的资本需求酌情予以注销、处置，或用作股份奖励或用作任何其他获准许用途。 ...

Group 1: Hong Kong Stocks - LeMo Technology (02539) surged nearly 17%, reaching a new high of 67.8 HKD, over 60% increase from the IPO price of 40 HKD [1] - Baixin An-B (02185) rose over 4% after announcing that its subsidiary completed the registration of the Iberis multi-polar renal artery radiofrequency ablation catheter system in New Zealand, the only product approved for both radial and femoral artery access for renal denervation [1] - Health Road (02587) increased over 2% as it announced plans to repurchase up to 100 million HKD of its shares in the open market, reflecting confidence in its business outlook [1] - Deutsche Bank Tianxia (02418) fell over 8% following a report that revealed 10 shareholders collectively held 98.9% of the company's issued H-shares, leaving only 1.1% for other investors [1] Group 2: Other Notable Stocks - Kailaiying (06821) rose nearly 2% as its Shanghai Fengxian commercial production base officially commenced operations, marking a significant upgrade in its biopharmaceutical CDMO capabilities [2] - Tianyu Semiconductor (02658) rebounded over 12% on its second day of trading, although still down 20% from its IPO price of 58 HKD [2] - Lithium stocks saw gains, with Ganfeng Lithium (01772) up 4.65%, Hongqiao Group (08137) up 2.15%, Tianqi Lithium (09696) up 3.29%, and CATL (03750) up 1.51% [2] - AAC Technologies (02018) rose nearly 2% after Alibaba launched its first self-developed flagship AI glasses, the Quark AI Glasses S1 [2] - Zhou Hei Ya (01458) increased over 5% as it announced the opening of its first overseas brand store in Malaysia on December 5, 2025 [2] Group 3: US Market Highlights - US mining stocks generally rose, with Albemarle (ALB.US) up 5.08% and MP Materials (MP.US) up 0.47%, amid reports of the US government planning to increase its stake in key mineral companies [5] - Paramount Skydance (PSKY.US) fell 9.82% after proposing a buyout of Warner Bros Discovery (WBD.US) at $30 per share, while Netflix (NFLX.US) offered $27.75 per share [5] - Intel (INTC.US) rose 2.25% after announcing it would retain its network and edge computing business, enhancing integration in AI and data center solutions [5] - Netflix (NFLX.US) dropped 2.89% while Warner Bros Discovery (WBD.US) rose 6.28% following Netflix's announcement of a $27.75 per share acquisition offer for Warner Bros [6] - Baidu (BIDU.US) increased by 5% as reports emerged that Kunlun Core is preparing for an IPO in Hong Kong, targeting early 2026 for its application [6]

智通财经APP获悉，健康之路(02587)午前涨超3%，截至发稿，涨2.67%，报4.99港元，成交额4653.23万 港元。 此外，董事会认为，本公司拥有充足的财务资源，可实施建议购回，且将不会损害其财务状况。建议购 回将不会以导致股份的公众持股量低于上市规则规定的最低百分比的方式进行，亦不会导致本公司股东 根据公司收购及合并守则作出强制性全面要约的责任。 消息面上，12月8日，健康之路发布公告，根据现行市况，本公司拟于未来五个月内行使购回授权，于 公开市场上购回本公司已发行股份，总代价不超过1亿港元(建议购回)。董事会认为，建议购回反映本 公司对其业务前景的信心，并将提升股东价值。建议购回将仅在董事会认为合适且符合本公司及其股东 的整体利益时方会进行。 ...

健康之路(02587)午前涨超3%，截至发稿，涨2.67%，报4.99港元，成交额4653.23万港元。 消息面上，12月8日，健康之路发布公告，根据现行市况，本公司拟于未来五个月内行使购回授权，于 公开市场上购回本公司已发行股份，总代价不超过1亿港元(建议购回)。董事会认为，建议购回反映本 公司对其业务前景的信心，并将提升股东价值。建议购回将仅在董事会认为合适且符合本公司及其股东 的整体利益时方会进行。 此外，董事会认为，本公司拥有充足的财务资源，可实施建议购回，且将不会损害其财务状况。建议购 回将不会以导致股份的公众持股量低于上市规则规定的最低百分比的方式进行，亦不会导致本公司股东 根据公司收购及合并守则作出强制性全面要约的责任。 ...

Group 1 - The Hang Seng Index opened with a slight decline of 0.07%, while the Hang Seng Tech Index saw a minor increase of 0.08% [1] - Notable performers in the Hong Kong stock market included Health Road, which rose over 3%, and several companies like SMIC and AAC Technologies, which increased by more than 2% [1] - The Hong Kong Stock Connect Tech ETF (513860) experienced a 0.13% rise, with a trading volume of 13.68 million yuan and a real-time premium rate of 0.01% [1] Group 2 - A significant trend in the Hong Kong stock market has been a surge in share buybacks, with 250 companies participating and repurchasing over 7 billion shares for a total amount exceeding 162 billion HKD as of December 4 [2] - The technology and consumer discretionary sectors have been the most active in terms of buybacks, driven by factors such as reasonable blue-chip valuations and companies holding ample cash [2] - The Hong Kong Stock Exchange's upcoming revision of the "treasury stock new regulations" in June 2024 will allow companies to repurchase shares without canceling them, thus lowering operational barriers for buybacks [2] Group 3 - The Hong Kong Stock Connect Tech ETF (513860) closely tracks the CSI Hong Kong Stock Connect Tech Index, which includes 50 large-cap technology companies with high R&D investment and rapid revenue growth [3] - The top ten weighted stocks in the index include major players like Alibaba, Tencent, SMIC, Xiaomi, and BYD [3] - According to CICC, the technology sector is expected to present significant investment opportunities by 2026, particularly in new infrastructure driven by technological innovation and structural opportunities arising from domestic demand recovery and high export growth [3]

格隆汇12月8日丨健康之路(02587.HK)发布公告，据现行市况，公司拟于未来五个月内行使购回授权， 于公开市场上购回公司已发行股份，总代价不超过1亿港元。所购回的任何股份将作为库存股份持有， 公司可根据市场情况及集团的资本需求酌情予以注销、处置，或用作股份奖励或用作任何其他获准许用 途。建议购回将完全由公司内部资源提供资金。全球发售股份所得款项净额将不会用于建议购回。 ...

智通财经APP讯，健康之路(02587)发布公告，根据现行市况，本公司拟于未来五个月内行使购回授权， 于公开市场上购回本公司已发行股份，总代价不超过1亿港元(建议购回)。建议购回将根据本公司组织 章程细则、香港联合交易所有限公司证券上市规则、公司收购、合并及股份回购守则、开曼群岛公司法 及所有其他适用法律及法规进行，所购回的任何股份将作为库存股份持有，本公司可根据市场情况及本 集团的资本需求酌情予以注销、处置，或用作股份奖励或用作任何其他获准许用途。 董事会认为，建议购回反映本公司对其业务前景的信心，并将提升股东价值。建议购回将仅在董事会认 为合适且符合本公司及其股东的整体利益时方会进行。此外，董事会认为，本公司拥有充足的财务资 源，可实施建议购回，且将不会损害其财务状况。此外，建议购回将不会以导致股份的公众持股量低于 上市规则规定的最低百分比的方式进行，亦不会导致本公司股东根据公司收购及合并守则作出强制性全 面要约的责任。 ...